Date of Defense
Spring 3-4-1996
Date of Graduation
4-1994
Department
Biological Sciences
First Advisor
Gail Zipp, Upjohn
Abstract
The alarming spread of AIDS has inspired a world-wide effort to disable the causative agent of AIDS, the human immunodeficiency virus (HIV). Pharmacia and Upjohn, Inc. has taken the first approach to AIDS research: AIDS is likely to be controlled by a combination of treatments that target the virus at various stages in its life cycle. The development of protease inhibitors and non-nucleoside reverse transcriptase inhibitors are two examples of target directed therapies. In this review, the author describes the overall process of pharmaceutical development of the HIV-Protease Inhibitor.
Recommended Citation
Lipkea, Carrie L., "Pharmaceutical Development of the HIV-Protease Inhibitor" (1996). Honors Theses. 213.
https://scholarworks.wmich.edu/honors_theses/213
Access Setting
Honors Thesis-Campus Only